Novel therapies in genitourinary cancer: an update
- PMID: 18694493
- PMCID: PMC2527326
- DOI: 10.1186/1756-8722-1-11
Novel therapies in genitourinary cancer: an update
Abstract
In recent years, new treatment for renal cell carcinoma (RCC) has been a spotlight in the field of cancer therapeutics. With several emerging agents branded as 'targeted therapy' now available, both medical oncologists and urologists are progressively more hopeful for better outcomes. The new remedies may provide patients with improved survival and at the same time less toxicity when compared to traditional cytotoxic agents. This article will center on current and emerging treatment strategies for advanced RCC and other GU malignancies with updates from 2008 annual ASCO meeting.
Similar articles
-
Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.Urol Oncol. 2021 Jul;39(7):437.e1-437.e9. doi: 10.1016/j.urolonc.2021.01.006. Epub 2021 Jan 23. Urol Oncol. 2021. PMID: 33495117 Free PMC article.
-
Novel immunotherapy combinations for genitourinary cancers.Expert Opin Biol Ther. 2020 Mar;20(3):253-262. doi: 10.1080/14712598.2020.1713086. Epub 2020 Jan 27. Expert Opin Biol Ther. 2020. PMID: 31914333 Review.
-
MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors.Clin Genitourin Cancer. 2015 Feb;13(1):e19-26. doi: 10.1016/j.clgc.2014.06.017. Epub 2014 Jul 3. Clin Genitourin Cancer. 2015. PMID: 25087088 Free PMC article.
-
Cabozantinib in genitourinary malignancies.Future Oncol. 2017 Apr;13(8):755-765. doi: 10.2217/fon-2016-0358. Epub 2016 Nov 15. Future Oncol. 2017. PMID: 27842445 Review.
-
New perspectives in advanced genitourinary malignancies.Tumori. 2012 Mar-Apr;98(2):267-9. doi: 10.1177/030089161209800215. Tumori. 2012. PMID: 22677996
References
-
- NCI Surveillance Epidemiology and End Results. wwwseercancergov. 2008.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources